newsfilter
← Earnings
Earnings Releases·

Serina Therapeutics — Third Quarter 2026 Earnings Summary

Serina Therapeutics reported a net loss of $7.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical activities. The company advanced its investigational Parkinson's disease treatment, SER-252, to Cohort 2 of its registrational study following a positive safety review by an independent committee. Cash and cash equivalents increased to $19.4 million as of September 30, 2026, supported by financing activities. Topline data from the single-ascending-dose portion of the SER-252 trial is expected in the first half of 2027.

Company
SERINA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology